| 常用名 | 阿普斯特 | CAS号 | 608141-41-9 |
|---|---|---|---|
| 价格 | ¥需询单/1kg | 纯度 | 99.5% |
| 备货期 | 1天 | 库存 | 现货 |
| 产品详情(用途,包装等)
Apremilast / CAS No: 608141-41-9 Name: Apremilast CAS No: 608141-41-9 Alisa: Apremilast (CC-10004) ; Otezla MF: C22H24N2O7S MW: 460.50 Deion: It's white powder Density: 1.382 g/cm3 Boiling point: 741.342 °C at 760 mmHg Flash point: 402.149 °C Usage: Anti psoriatic arthritis ; PDE4 and TNF alpha inhibitors Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis.Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis. |